Day: February 24, 2022

Commercial Momentum, Organic Reinvestment, and M&A Support 2022 Outlook And Long-Term Growth Opportunities PHOENIX, Feb. 24, 2022 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini Holdings” or the “Company”) (Nasdaq: WSC), the North American leader in innovative flexible work space and portable storage solutions, today announced fourth quarter and full year 2021 results and provided an update on operations and the current market environment, including the following highlights:Continued execution and commercial momentum in all operating segments resulted in fourth quarter revenue of $518 million, net income of $74 million, and Adjusted EBITDA of $211 million; full year 2021 revenue of $1,895 million, net income of $160 million, and Adjusted EBITDA of $740 million. Invested $147 million in and fully...

TORONTO and MINNEAPOLIS, Feb. 24, 2022 (GLOBE NEWSWIRE) — Ceridian (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, today announced the appointments of Chris Armstrong to Executive Vice President and Chief Operating Officer, and Steve Holdridge to Executive Vice President and Chief Customer Officer. Armstrong and Holdridge will help accelerate the company’s growth and continue to increase the value that customers gain from the Dayforce platform. As Chief Operating Officer, Armstrong will lead global operations, focused on driving scale, efficiency, and growth as the company continues to expand around the world. Since joining Ceridian in 2004, Armstrong has held several senior leadership roles, most recently overseeing the global customer office and the customer experience. In his expanded role...

Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM, OTCQX:WLBMF), (“Wallbridge” or the “Company”) today announced that further to its press release earlier today, that it has completed its previously-announced non-brokered private placement of 24,611,351 National flow-through common shares (the “National FT Shares”) and 12,357,000 Quebec flow-through common shares (the “Quebec FT Shares”) for aggregate gross proceeds of C$14,172,570 (the “Private Placement”). The National FT Shares were issued at a price of C$0.37 and the Quebec FT Shares at a price of C$0.41. All securities issued pursuant to the Private Placement will have a four month and one day statutory hold period. The gross proceeds from the Private Placement...

 Key 2021 and post period events:Appointment of Dr. Paul Stoffels1 as new CEO, effective 1 April 2022, following planned retirement of CEO and co-founder Onno van de Stolpe Jyseleca sales booked by Galapagos in Europe were €14.8 million out of a total in-market performance of €25.7 million Jyseleca (filgotinib) approved for ulcerative colitis (UC) in Europe and Great Britain, reimbursement for rheumatoid arthritis (RA) secured in 14 countries Patient enrollment completed in the DIVERSITY Phase 3 program with filgotinib in Crohn’s Disease (CD) Discontinuation of development of ziritaxestat, GLPG1690, in Phase 3 program in idiopathic pulmonary fibrosis (IPF) First patient results with salt inducible kinase (SIK) 2/3 inhibitor GLPG3970 support further work on this novel pharmacology Activity observed with selective tyrosine kinase (TYK)...

Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022      Phase 1b study in Cognitive Impairment Associated with Schizophrenia (CIAS) enrollment ongoing; topline data expected in H2 2022      Phase 2a study in Alzheimer’s Disease with vascular pathology (ADv) enrollment ongoing CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced today clinical development updates for CY6463, its lead program, and additional corporate progress. “We are developing CY6463 as a potentially transformative medicine for cognitive impairment associated with certain CNS diseases that are lacking...

– BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER – – Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3 million – – Cash Balance of $186.4 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter and full-year 2021 and provided a corporate update. “We strengthened the fundamentals of our pain portfolio in the face of challenging market dynamics throughout 2021, achieved key operational objectives, and completed a restructuring that positions Collegium to embark upon a period of growth and value creation,” said Joe Ciaffoni, President and Chief Executive Officer of...